{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:43:01Z","timestamp":1781502181492,"version":"3.54.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM1269128"],"award-info":[{"award-number":["GM1269128"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23GM129660"],"award-info":[{"award-number":["K23GM129660"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM1269128"],"award-info":[{"award-number":["GM1269128"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23GM129660"],"award-info":[{"award-number":["K23GM129660"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A defining feature of protracted sepsis is development of immunosuppression that is thought to be a major driving force in the morbidity and mortality associated with the syndrome. The immunosuppression that occurs in sepsis is characterized by profound apoptosis-induced depletion of CD4 and CD8 T cells and severely impaired T cell function. OX40, a member of the TNF receptor superfamily, is a positive co-stimulatory molecule expressed on activated T cells. When engaged by OX40 ligand, OX40 stimulates T cell proliferation and shifts the cellular immune phenotype toward TH1 with increased production of cytokines that are essential for control of invading pathogens. The purpose of the present study was to determine if administration of agonistic Ab to OX40 could reverse sepsis-induced immunosuppression, restore T cell function, and improve survival in a clinically relevant animal model of sepsis. The present study demonstrates that OX40 agonistic Ab reversed sepsis-induced impairment of T cell function, increased T cell IFN-\u03b3 production, increased the number of immune effector cells, and improved survival in the mouse cecal ligation and puncture model of sepsis. Importantly, OX40 agonistic Ab was not only effective in murine sepsis but also improved T effector cell function in PBMCs from patients with sepsis. The present results provide support for the use of immune adjuvants that target T cell depletion and T cell dysfunction in the therapy of sepsis-induced immunosuppression. In addition to the checkpoint inhibitors anti-PD-1 and anti-PD-L1, OX40 agonistic Ab may be a new therapeutic approach to the treatment of this highly lethal disorder.<\/jats:p>","DOI":"10.1002\/jlb.5hi0720-043r","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T09:16:40Z","timestamp":1597655800000},"page":"697-708","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Frontline Science: OX40 agonistic antibody reverses immune suppression and improves survival in sepsis"],"prefix":"10.1093","volume":"109","author":[{"given":"Jacqueline","family":"Unsinger","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Washington University School of Medicine , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H","family":"Walton","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Washington University School of Medicine , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Blood","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Washington University School of Medicine , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Tenney","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Leads Discovery & Optimization , Lawrenceville, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Quigley","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Oncology Discovery Biology , Redwood City, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M","family":"Drewry","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Washington University School of Medicine , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-3655","authenticated-orcid":true,"given":"Richard S","family":"Hotchkiss","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Washington University School of Medicine , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"2023032108364016500_jlb10789-cit-0001","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2023032108364016500_jlb10789-cit-0002","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1208623","article-title":"Severe sepsis and septic shock","volume":"369","author":"Angus","year":"2013","journal-title":"N Engl J Med"},{"key":"2023032108364016500_jlb10789-cit-0003","doi-asserted-by":"crossref","first-page":"16045","DOI":"10.1038\/nrdp.2016.45","article-title":"Sepsis and septic shock","volume":"2","author":"Hotchkiss","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2023032108364016500_jlb10789-cit-0004","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMra021333","article-title":"The pathophysiology and treatment of sepsis","volume":"348","author":"Hotchkiss","year":"2003","journal-title":"N Engl J Med"},{"key":"2023032108364016500_jlb10789-cit-0005","doi-asserted-by":"crossref","first-page":"e98819","DOI":"10.1371\/journal.pone.0098819","article-title":"Reactivation of multiple viruses in patients with sepsis","volume":"9","author":"Walton","year":"2014","journal-title":"PLoS One"},{"key":"2023032108364016500_jlb10789-cit-0006","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.surg.2018.04.011","article-title":"Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery","volume":"164","author":"Efron","year":"2018","journal-title":"Surgery"},{"key":"2023032108364016500_jlb10789-cit-0007","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ccc.2017.08.007","article-title":"Management of sepsis-induced immunosuppression","volume":"34","author":"Venet","year":"2018","journal-title":"Crit Care Clin"},{"key":"2023032108364016500_jlb10789-cit-0008","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMcibr1404664","article-title":"Parallels between cancer and infectious disease","volume":"371","author":"Hotchkiss","year":"2014","journal-title":"N Engl J Med"},{"key":"2023032108364016500_jlb10789-cit-0009","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00134-010-2088-x","article-title":"Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome","volume":"37","author":"Hall","year":"2011","journal-title":"Intensive Care Med"},{"key":"2023032108364016500_jlb10789-cit-0010","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98960","article-title":"Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial","volume":"3","author":"Francois","year":"2018","journal-title":"JCI Insight"},{"key":"2023032108364016500_jlb10789-cit-0011","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/CCM.0000000000003685","article-title":"Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559)","volume":"47","author":"Hotchkiss","year":"2019","journal-title":"Crit Care Med"},{"key":"2023032108364016500_jlb10789-cit-0012","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00134-019-05704-z","article-title":"Immune checkpoint inhibition in sepsis: a phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab","volume":"45","author":"Hotchkiss","year":"2019","journal-title":"Intensive Care Med"},{"key":"2023032108364016500_jlb10789-cit-0013","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/infdis\/jis383","article-title":"Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis","volume":"206","author":"Unsinger","year":"2012","journal-title":"J Infect Dis"},{"key":"2023032108364016500_jlb10789-cit-0014","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1073\/pnas.0809422106","article-title":"PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis","volume":"106","author":"Huang","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023032108364016500_jlb10789-cit-0015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1189\/jlb.0110037","article-title":"Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis","volume":"88","author":"Brahmamdam","year":"2010","journal-title":"J Leukoc Biol"},{"key":"2023032108364016500_jlb10789-cit-0016","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/cc12711","article-title":"Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis","volume":"17","author":"Chang","year":"2013","journal-title":"Crit Care"},{"key":"2023032108364016500_jlb10789-cit-0017","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1093\/jac\/dkq359","article-title":"A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia","volume":"65","author":"Patel","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2023032108364016500_jlb10789-cit-0018","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N Engl J Med"},{"key":"2023032108364016500_jlb10789-cit-0019","doi-asserted-by":"crossref","first-page":"e63818","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1, in patients with chronic hepatitis C virus infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS One"},{"key":"2023032108364016500_jlb10789-cit-0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-07-741025","article-title":"The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy","volume":"131","author":"Buchan","year":"2018","journal-title":"Blood"},{"key":"2023032108364016500_jlb10789-cit-0021","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molimm.2017.01.006","article-title":"OX40: structure and function - What questions remain","volume":"83","author":"Willoughby","year":"2017","journal-title":"Mol Immunol"},{"key":"2023032108364016500_jlb10789-cit-0022","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.1073\/pnas.1031788100","article-title":"Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis","volume":"100","author":"Hotchkiss","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023032108364016500_jlb10789-cit-0023","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.chom.2015.03.007","article-title":"PD-1 co-inhibitory and OX40 co-stimulatory crosstalk regulates helper T cell differentiation and anti-plasmodium humoral immunity","volume":"17","author":"Zander","year":"2015","journal-title":"Cell Host & Microbe"},{"key":"2023032108364016500_jlb10789-cit-0024","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah5766","article-title":"An OX40\/OX40L interaction directs successful immunity to hepatitis B virus","volume":"10","author":"Publicover","year":"2018","journal-title":"Sci Transl Med"},{"key":"2023032108364016500_jlb10789-cit-0025","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1128\/IAI.01213-09","article-title":"Characterization and modulation of the immunosuppressive phase of sepsis","volume":"78","author":"Muenzer","year":"2010","journal-title":"Infect Immun"},{"key":"2023032108364016500_jlb10789-cit-0026","doi-asserted-by":"crossref","first-page":"e0199497","DOI":"10.1371\/journal.pone.0199497","article-title":"Restoration of T Cell function in multi-drug resistant bacterial sepsis after interleukin-7, anti-PD-L1, and OX-40 administration","volume":"13","author":"Thampy","year":"2018","journal-title":"PLoS One"},{"key":"2023032108364016500_jlb10789-cit-0027","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.4049\/jimmunol.1900637","article-title":"IL-10 has differential effects on the innate and adaptive immune systems of septic patients","volume":"203","author":"Mazer","year":"2019","journal-title":"J Immunol"},{"key":"2023032108364016500_jlb10789-cit-0028","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/eji.1830260805","article-title":"OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for OX40 ligand","volume":"26","author":"al-Shamkhani","year":"1996","journal-title":"Eur J Immunol"},{"key":"2023032108364016500_jlb10789-cit-0029","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1158\/1078-0432.CCR-19-0526","article-title":"An integrative approach to inform optimal administration of OX40 agonist antibodies in patients with advanced solid tumors","volume":"25","author":"Wang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2023032108364016500_jlb10789-cit-0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2500\/108854193778792830","article-title":"Evaluation of delayed hypersensitivity: from PPD to poison ivy","volume":"14","author":"Rosenstreich","year":"1993","journal-title":"Allergy Proc"},{"key":"2023032108364016500_jlb10789-cit-0031","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1084\/jem.183.5.2185","article-title":"The human OX40\/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells","volume":"183","author":"Imura","year":"1996","journal-title":"J Exp Med"},{"key":"2023032108364016500_jlb10789-cit-0032","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.168.5.2493","article-title":"Depletion of dendritic cells, but not macrophages, in patients with sepsis","volume":"168","author":"Hotchkiss","year":"2002","journal-title":"J Immunol"},{"key":"2023032108364016500_jlb10789-cit-0033","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.4049\/jimmunol.1000404","article-title":"OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis","volume":"185","author":"Karulf","year":"2010","journal-title":"J Immunol"},{"key":"2023032108364016500_jlb10789-cit-0034","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2011.1829","article-title":"Immunosuppression in patients who die of sepsis and multiple organ failure","volume":"306","author":"Boomer","year":"2011","journal-title":"JAMA"},{"key":"2023032108364016500_jlb10789-cit-0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00000658-199522240-00011","article-title":"The delayed hypersensitivity response and host resistance in surgical patients. 20 years later","volume":"222","author":"Christou","year":"1995","journal-title":"Ann Surg"},{"key":"2023032108364016500_jlb10789-cit-0036","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/JLB.4CE1117-447","article-title":"Immunotherapy: it is not just for cancer anymore","volume":"103","author":"Moldawer","year":"2018","journal-title":"J Leukoc Biol"},{"key":"2023032108364016500_jlb10789-cit-0037","doi-asserted-by":"crossref","first-page":"21779","DOI":"10.18632\/oncotarget.4973","article-title":"OX40\/OX40L axis: not a friend in autoimmunity","volume":"6","author":"Ueno","year":"2015","journal-title":"Oncotarget"},{"key":"2023032108364016500_jlb10789-cit-0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2015.00034","article-title":"OX40 agonists and combination immunotherapy: putting the pedal to the metal","volume":"5","author":"Linch","year":"2015","journal-title":"Front Oncol"}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/JLB.5HI0720-043R","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/JLB.5HI0720-043R","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/am-pdf\/10.1002\/JLB.5HI0720-043R","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/109\/4\/697\/49460775\/jlb10789.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/109\/4\/697\/49460775\/jlb10789.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T21:20:47Z","timestamp":1679433647000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/109\/4\/697\/7032802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,8,17]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jlb.5hi0720-043r","relation":{},"ISSN":["0741-5400","1938-3673"],"issn-type":[{"value":"0741-5400","type":"print"},{"value":"1938-3673","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"2020-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}